ABOUT US
Unlocking the power of SPRING.
We are reinventing genetic medicine to be precise, scalable, long-lasting and safe. A whole new world awaits.
Avecris is developing the SPRING DNA™ platform. Our vision is to improve human health by developing transformational medicines that were once thought unimaginable.
SPRING DNA was invented by a team of non-viral gene delivery experts based at the National University of Singapore. The team used rational design combined with its expertise in biosynthetic manufacturing to produce a unique structure for a DNA vector, which led to dramatically enhanced delivery and expression.
Further refinements led to the development of the universal SPRING DNA template, a proprietary, minimalistic gene construct engineered with flexible “spring-like” loop designs. These loops can be used to conjugate helper functions, such as antibodies, aptamers and peptides, to achieve tissue-specific targeting.
SPRING DNA is more stable than mRNA and next-wave RNA, such as circular and self-amplifying RNA. This makes SPRING DNA capable of long-lasting protein expression, providing a durable therapeutic effect to treat chronic disease.
SPRING DNA are the smallest expression vectors reported; the minimalistic size and lack of free ends means they are exonuclease resistant and do not trigger the innate immune system.
Gene expression from SPRING DNA can also be precisely controlled with an innovative on/off switch invented by Avecris, allowing it to express in only the intended cell type, with no observed off-targeting.
The low-cost, scalable and reliable manufacturing process gives SPRING DNA the potential to bring down the cost and increase the availability of gene therapy and genetic vaccination.
